NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
Company Research
Source: Yahoo! Finance
late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 30,000 of NewAmsterdam's ordinary shares to three non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price per share equal to $21.97, which represents the closing market price on the Nasdaq Stock Market of the Company's ordinary shares on May 1, 2024, the grant date. The shares s
Show less
Read more
Impact Snapshot
Event Time:
NAMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAMS alerts
High impacting NewAmsterdam Pharma Company N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NAMS
News
- NewAmsterdam Pharma (NASDAQ: NAMS) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results [Yahoo! Finance]Yahoo! Finance
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsGlobeNewswire
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 [Yahoo! Finance]Yahoo! Finance
NAMS
Sec Filings
- 5/9/24 - Form ARS
- 5/9/24 - Form DEF
- 5/9/24 - Form 8-K
- NAMS's page on the SEC website